Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
Add more filters

Affiliation country
Publication year range
2.
Updates Surg ; 75(3): 735-741, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36877431

ABSTRACT

COVID-19 pandemic had an impact on surgical activities. The aim of this multi-centric, retrospective study was to evaluate the impact of the COVID-19 pandemic on breast surgery. The patients who operated during the pre-pandemic year 2019 were compared to those operated in 2020. Fourteen Breast Care Units provided data on breast surgical procedures performed in 2020 and 2019: total number of breast-conserving surgery (BCS), number of 1st level oncoplastic breast surgery (OBS), number of 2nd level OBS; total number of mastectomies, mastectomies without reconstruction, mastectomies with a tissue expander, mastectomies with direct to implant (DTI) reconstruction, mastectomies with immediate flap reconstruction; total number of delayed reconstructions, number of expanders to implant reconstructions, number of delayed flap reconstructions. Overall 20.684 patients were included: 10.850 (52.5%) operated during 2019, and 9.834 (47.5%) during 2020. The overall number of breast oncologic surgical procedures in all centers in 2020 was 8.509, compared to 9.383 in 2019 (- 9%). BCS decreased by 744 cases (- 13%), the overall number of mastectomies decreased by 130 cases (- 3.5%); mastectomy-BCS ratio was 39-61% in 2019, and 42-58% in 2020. Regarding immediate reconstructive procedures mastectomies with DTI reconstruction increased by 166 cases (+ 15%) and mastectomies with immediate expander reconstruction decreased by 297 cases (- 20%). Breast-delayed reconstructive procedures in all centers in 2020 were 142 less than in 2019 (- 10%). The outburst of the COVID-19 pandemic in 2020 determined an implemented number of mastectomies compared to BCS, an implemented number of immediate breast reconstructions, mainly DTI, and a reduction of expander reconstruction.


Subject(s)
Breast Neoplasms , COVID-19 , Mammaplasty , Humans , Female , Mastectomy , Retrospective Studies , Pandemics , Breast Neoplasms/surgery , Mammaplasty/methods
3.
Eur Rev Med Pharmacol Sci ; 16(7): 966-71, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22953647

ABSTRACT

BACKGROUND: Breast conserving surgery (BCS) combined with postoperative radiotherapy has become the gold standard of locoregional treatment for the majority of patients with early-stage breast cancer, offering equivalent survival and improved body image and lifestyle scores as compared to mastectomy. In an attempt to optimize the oncologic safety and cosmetic results of BCS, oncoplastic procedures (OPP) have been introduced in recent years combining the best principles of surgical oncology with those of plastic surgery. However, even with the use of OPP, cosmetic outcomes may result unsatisfying when a large volume of parenchyma has to be removed, particularly in small-medium size breasts. AIM: The aim of this article is to report our preliminary results with the use of oxidized regenerate cellulose (ORC) (Tabotamp fibrillar, Johnson & Johnson; Ethicon, USA) as an agent to prevent cosmetic defects in patients undergoing OPP for breast cancer and to analyze the technical refinements that can enhance its efficacy in optimizing cosmetic defects. METHODS: Different OPP are selected based on the location and size of the tumor as well as volume and shape of the breast. After excision of the tumor, glandular flaps are created by dissection of the residual parenchyma from the pectoralis and serratus muscles and from the skin. After careful haemostasis, five layers of ORC are positioned on the pectoralis major in the residual cavity and covered by advancement of the glandular flaps. Two additional layers of ORC are positioned above the flaps and covered by cutaneous-subcutaenous flaps. RESULTS: The use of ORC after OPP has shown promising preliminary results, indicating a good tolerability and positive effects on cosmesis. CONCLUSIONS: This simple and reliable surgical technique may allow not only to reduce the rate of post-operative bleeding and infection at the surgical site but also to improve cosmetic results.


Subject(s)
Breast Neoplasms/surgery , Cellulose, Oxidized/therapeutic use , Mammaplasty , Mastectomy, Segmental , Surgical Flaps , Breast Neoplasms/pathology , Cicatrix/etiology , Cicatrix/prevention & control , Depsipeptides , Female , Humans , Mammaplasty/adverse effects , Mastectomy, Segmental/adverse effects , Postoperative Hemorrhage/etiology , Postoperative Hemorrhage/prevention & control , Rome , Surgical Flaps/adverse effects , Surgical Wound Infection/etiology , Surgical Wound Infection/prevention & control , Time Factors , Treatment Outcome
4.
Eur Rev Med Pharmacol Sci ; 16(11): 1530-40, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23111966

ABSTRACT

Oncoplastic surgery of the breast (OPS) has generated great excitement over the past years and has become an integrated component of the surgical treatment of breast cancer. Oncoplastic surgical procedures associate the best surgical oncologic principles to achieve wide tumor-free margins with the best principles of plastic surgery to optimize cosmetic outcomes. Thanks to oncoplastic techniques, the role of breast conserving surgery (BCS) has been extended to include a group of patients who would otherwise require mastectomy to achieve adequate tumor clearance. As OPS continues to gain acceptance and diffusion, an optimal and systematic approach to these techniques is becoming increasingly necessary. This article has the aim to review the essential principles and techniques associated with oncoplastic surgery, based on the data acquired through an extensive search of the PUBMED and MEDLINE database for articles published using the key words "breast cancer oncoplastic surgery". This review analyzes possible the advantages", classifications, indications, and the criteria for a proper selection of oncoplastic techniques to facilitate one's ability to master these procedures and make OPS a safe and an effective procedure.


Subject(s)
Breast Neoplasms/surgery , Mammaplasty , Mastectomy, Segmental , Female , Humans
5.
Int J Med Inform ; 165: 104832, 2022 09.
Article in English | MEDLINE | ID: mdl-35842978

ABSTRACT

BACKGROUND: Limited research has examined mobile phone-based platforms for survey recruitment, especially during the COVID-19 pandemic in Brazil. Our objective was to investigate the feasibility and representativeness of mobile phone-based advertisement during a preliminary study about COVID-19 vaccine hesitation in Brazil. Moreover, we evaluate whether the older population can be reached through mobile phone-based platforms of the survey. METHODS: We conducted a study in December 2021 based on a preliminary survey about the COVID-19 vaccine hesitation in Assis, Brazil, Sao Paulo state. From a list of the adult population hesitant about the second dose of the COVID-19 vaccine, we sent a mobile phone-based advertisement inviting the participants to answer the survey for one week. The respondent's data were collected in a Google form platform. The comparison between the target population and the respondents was made using the Chi-squared test and the Welch's test, using a P-value of 0.05 as significative. RESULTS: The response rate was 9.99% after one week. The mean age of the respondent group was 33.97 (SD 14.99) and 35.05 (SD 14.19) of the population, with a P-value of 0.192 and a Cohen's d coefficient of 0.0754, corresponding to a small effect size between groups. We demonstrate that the mobile phone-based survey is a feasible and representative strategy during the pandemics in Brazil. Moreover, the older population respondent was representative. CONCLUSION: We achieved a representative sample of respondents using the mobile phone-based survey in Brazil. Furthermore, it was representative of all sociodemographic and health characteristics assessed. Finally, these findings suggest that the method is a highly feasible and economical means of recruiting for survey research.


Subject(s)
COVID-19 , Cell Phone , Text Messaging , Adult , Brazil/epidemiology , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines , Cross-Sectional Studies , Humans , Pandemics/prevention & control
6.
Eur Rev Med Pharmacol Sci ; 25(2): 661-668, 2021 01.
Article in English | MEDLINE | ID: mdl-33577020

ABSTRACT

OBJECTIVE: To predict the occult tumor involvement of nipple-areola complex (NAC) using preoperative MR imaging and to investigate whether the intraoperative histopathological examination of the subareolar tissue is still necessary. PATIENTS AND METHODS: Out of 712 patients submitted to nipple-sparing mastectomy (NSM) between 2014 and 2019, we selected 188 patients who underwent preoperative breast MRI. Breast MRI and intraoperative histopathological examination of the subareolar tissue were performed to predict NAC involvement at permanent pathology. All parameters were correlated with final pathological NAC assessment by univariate and multivariate analysis. RESULTS: Forty-three patients (22.9%) had tumor involvement of the NAC. At univariate analysis, non-mass enhancement type (p = 0.009), multifocality/multicentricity (p = 0.002), median tumor size (p < 0.001), median tumor-NAC distance measured by MRI (p < 0.001), tumor-NAC distance ≤ 10 mm (p < 0.001) and tumor-NAC distance ≤ 20 mm (p < 0.001), and lymphovascular invasion (p = 0.001) were significantly correlated with NAC involvement. At multivariate analysis, only tumor-NAC distance ≤ 10 mm retained statistical significance. The sensitivity and specificity of MRI tumor-NAC distance ≤ 10 mm were 79.1% and 97.2% and those of intraoperative pathologic assessment were 74,4% and 100%, respectively. CONCLUSIONS: Tumor-NAC distance is the only reliable MRI characteristic that can predict NAC involvement in breast cancer patients. Although several cut-offs showed promising performances, intraoperative pathologic assessment is still mandatory.


Subject(s)
Breast Neoplasms/diagnostic imaging , Magnetic Resonance Imaging , Nipples/diagnostic imaging , Biopsy , Breast Neoplasms/surgery , Female , Humans , Mastectomy , Middle Aged , Multivariate Analysis , Nipples/surgery
7.
Eur Rev Med Pharmacol Sci ; 25(4): 1910-1915, 2021 02.
Article in English | MEDLINE | ID: mdl-33660830

ABSTRACT

OBJECTIVE: Triple-negative breast cancers (TNBC) include a heterogeneous group of diseases, characterized by the lack of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) expression. TNBC that shows an overexpression of the androgen receptor (AR) defines the phenotype known as "luminal androgen receptor" (LAR), while the absence of the AR defines a "quadruple negative breast cancer" (QNBC). Several reports have associated AR positivity with a lower response to neoadjuvant chemotherapy (NAC), while divergent data have been reported about the impact of AR positivity on survival. The aim of this study was to retrospectively review our series of patients with TNBC tested for AR and submitted to NAC and compare pathologic complete response (pCR) rates in patients with a LAR phenotype or with QNBC. PATIENTS AND METHODS: The clinical records of all patients with TNBC tested for AR that underwent NAC at our Institution from January 1, 2015 to June 30, 2019 were reviewed. Histopathological features as well as ER, PgR, Ki67, HER2 values, clinical and pathological stage, and results of BRCA gene expression profiling were registered for all patients. RESULTS: Of the 145 TNBC patients treated by NAC, 20 (13.8%) had a LAR phenotype, while 125 (86.2%) had a QNBC. Overall, a pCR was achieved in 52 patients (35.8%). Patients with LAR phenotype had a lower rate of pCR as compared to patients with QNBC phenotype (25% vs. 37.6%). High Ki67 values (>50%) were observed less frequently in patients with a LAR phenotype (50% vs. 76.8% in QNBC). CONCLUSIONS: Our data seem to confirm that the LAR phenotype is associated to lower rates of pCR after neoadjuvant chemotherapy; routine assessment of AR expression in addition to classical biomarkers in patients with TNBC could help to better personalize treatment.


Subject(s)
Receptors, Androgen/genetics , Triple Negative Breast Neoplasms/therapy , Female , Humans , Middle Aged , Neoadjuvant Therapy , Receptors, Androgen/metabolism , Triple Negative Breast Neoplasms/diagnosis , Triple Negative Breast Neoplasms/metabolism
8.
Breast ; 45: 56-60, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30877870

ABSTRACT

BACKGROUND: Breast angiosarcoma is a malignant mesenchymal neoplasm, which accounts for approximately 2% of all soft tissue sarcomas. Secondary breast angiosarcoma (SBA) may be related to chronic lymphedema after a mastectomy with lymph node dissection (Stewart Treves syndrome) and previous radiotherapy for complications from breast radiation treatment. It is a very rare condition; therefore, diagnosis and management are still a challenge. METHODS: The ANISC collected SBA data by means of a survey sent to all Italian breast centres in the ANISC. The clinicopathological characteristics and the management of this disease were analysed. RESULTS: Twenty-four centres participated in this survey in which 112 cases of SBA were analysed. The median age of the women with SBA was 68.9 years and it appeared approximately 90 months after the first irradiation for breast cancer. In 92% of cases, a mastectomy was performed without axillary dissection for those patients having a high grade of SBA (74.2%). The prognosis was worse in the high-grade cases (overall survival-OS: 36 months) as compared with the low-grade cases (OS: 48 months). After a follow-up of 5 years, 50.5% of the patients were still alive. Disease-free survival (DFS) was 35 months, and there were no differences between the groups of patients with either high- or low-grade histology. CONCLUSIONS: Secondary breast angiosarcoma is a very aggressive disease associated with a short survival outcome. The surgical approach still remains an important step in the course of treatment; furthermore, an accurate histological examination is helpful in establishing the prognosis of the patient. A mastectomy is mandatory. A longer OS was observed in patients with low-grade angiosarcoma as compared to high-grade angiosarcoma (C.I. 40-57 vs. 31-41 months).


Subject(s)
Breast Neoplasms/mortality , Hemangiosarcoma/mortality , Neoplasms, Second Primary/mortality , Postoperative Complications/mortality , Aged , Breast Neoplasms/etiology , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Female , Hemangiosarcoma/complications , Hemangiosarcoma/etiology , Hemangiosarcoma/surgery , Humans , Italy/epidemiology , Lymph Node Excision/adverse effects , Lymphangiosarcoma/complications , Mastectomy/mortality , Neoplasms, Second Primary/etiology , Neoplasms, Second Primary/surgery , Postoperative Complications/etiology , Prognosis , Retrospective Studies , Surgeons/statistics & numerical data , Surveys and Questionnaires
9.
Eur Rev Med Pharmacol Sci ; 12(6): 387-96, 2008.
Article in English | MEDLINE | ID: mdl-19146201

ABSTRACT

In the attempt to optimise the balance between the risk of local recurrence and the cosmetic outcomes in breast surgery, new surgical procedures, so-called oncoplastic techniques, have been introduced in recent years. The term oncoplastic surgery refers to surgery on the basis of oncological principles during which the techniques of plastic surgery are used, mostly for reconstructive and cosmetic reasons. The advantage of the oncoplastic surgery for breast cancer is the possibility of performing a wider excision of the tumour with a good cosmetic result. Oncoplastic surgery is a broad concept that can be used for several different combinations of oncological surgery and plastic surgery: excision of the tumour by reduction mammoplasty, tumour excision followed by remodelling mammoplasty, mastectomy with immediate reconstruction of the breast and partial mastectomy with reconstruction. Careful patient selection and preoperative planning are key components for the success of any oncoplastic operation for breast cancer. Accurate preoperative evaluation of the clinical and biological features of the tumour as well as of the morphological aspects of the breast allow the surgeon to make a decision if a conservative or radical approach is preferable and select the most effective oncoplastic surgical technique. In this review we summarise the indications, advantages and limitations of several oncoplastic procedures.


Subject(s)
Breast Neoplasms/surgery , Mastectomy, Segmental/methods , Female , Humans , Mammaplasty , Mastectomy, Simple , Surgical Flaps
10.
G Chir ; 29(1-2): 23-7, 2008.
Article in English | MEDLINE | ID: mdl-18252144

ABSTRACT

Conservative surgery with radiation therapy is the standard treatment for early-stage breast cancer. Nevertheless, the patients with subareolar breast cancer have been often excluded from breast-conserving surgery and treated with mastectomy because of the unacceptable cosmetic effect associated with the resection of the nipple-areola complex (NAC), as well as oncologic concerns about multicentricity or multifocality associated with these tumours. We show a conservative "oncoplastic technique" in which the resection of the central portion of the breast, including the NAC, can allow a wide excision of the tumour with uninvolved margins of resection and good cosmetic results.


Subject(s)
Breast Neoplasms/surgery , Mastectomy, Segmental/methods , Nipples/surgery , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Carcinoma/surgery , Female , Humans , Middle Aged , Neoplasm Invasiveness , Radiotherapy, Adjuvant , Treatment Outcome
11.
Eur Rev Med Pharmacol Sci ; 11(5): 283-9, 2007.
Article in English | MEDLINE | ID: mdl-18074936

ABSTRACT

Locally advanced breast cancer represents a wide variety of neoplasms and constitutes approximately 10%-20% of the newly diagnosed breast cancers. These cancers may have widely different clinical and biological characteristics. According to the American Joint Committee on Cancer (AJCC) staging system, all of stage III disease is considered locally advanced. The clinical treatment of locally advanced breast cancer is complex and should be tailored to the individual patient. In this paper we discuss the options of management of locally advanced breast cancer, focusing on a multidisciplinary approach through a combined-modality care involving surgery, radiotherapy and systemic therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/therapy , Mastectomy , Patient Care Team , Patient Selection , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Chemotherapy, Adjuvant , Female , Humans , Neoplasm Invasiveness , Neoplasm Staging , Radiotherapy, Adjuvant , Treatment Outcome
12.
Minerva Chir ; 62(4): 249-55, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17641585

ABSTRACT

The term locally advanced breast cancer (LABC) encompasses a heterogeneous group of breast neoplasms; in the last revision of the American Joint Committee on Cancer (AJCC) staging system, all of stage III disease is considered locally advanced. LABC constitutes up to 20% of breast cancer in medically underserved populations in the United States and up to 75% of breast cancers in developing countries. The prognosis depends on tumor size, extent of lymph node involvement, and the presence or absence of an inflammatory component. The clinical management of LABC is complex and should be tailored to the individual patient. However, a multidisciplinary approach is always recommended combining surgery, radiotherapy and systemic therapy (chemotherapy and/or hormone therapy). In this paper, we discuss the possible options in the management of operable (stage IIIA) and inoperable (stage IIIB-IIIC) LABC.


Subject(s)
Breast Neoplasms/pathology , Breast Neoplasms/therapy , Algorithms , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Chemotherapy, Adjuvant , Decision Trees , Female , Humans , Mastectomy/methods , Neoadjuvant Therapy/methods , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , Radiotherapy, Adjuvant , Treatment Outcome
13.
BMC Cancer ; 6: 193, 2006 Jul 19.
Article in English | MEDLINE | ID: mdl-16854225

ABSTRACT

BACKGROUND: Distant spread from breast cancer is commonly found in bones, lungs, liver and central nervous system. Metastatic involvement of peritoneum and retroperitoneum is unusual and unexpected. CASE PRESENTATION: We report the case of a 67 year-old-woman who presented with gastrointestinal symptoms which revealed to be the clinical manifestations of peritoneal and retroperitoneal metastatic spread of an invasive lobular breast cancer diagnosed 15 years before. CONCLUSION: To the best of our knowledge, the case presented is the third one reported in literature showing a wide peritoneal and extraperitoneal diffusion of an invasive lobular breast cancer. The long and complex diagnostic work up which led us to the diagnosis is illustrated, with particular emphasis on the multidisciplinary approach, which is mandatory to obtain such a result in these cases. Awareness of such a condition by clinicians is mandatory in order to make an early diagnosis and start a prompt and correct therapeutic approach.


Subject(s)
Breast Neoplasms/complications , Breast Neoplasms/secondary , Gastrointestinal Diseases/etiology , Neoplasm Invasiveness/diagnosis , Peritoneal Cavity/pathology , Retroperitoneal Space/pathology , Aged , Biopsy , Breast Neoplasms/ultrastructure , Female , Gastrointestinal Diseases/pathology , Humans
14.
Cancer Res ; 57(23): 5406-9, 1997 Dec 01.
Article in English | MEDLINE | ID: mdl-9393767

ABSTRACT

We assayed methyl-p-hydroxyphenyllactate esterase (MeHPLAase) activity in 48 cases of primary breast cancer. MeHPLAase activity did not show significant correlation with estrogen receptor and progesterone receptor levels. No significant relationship was found between enzymatic activity and tumor diameter, lymph node status, mitotic activity, degree of nuclear differentiation, and proportion of the S-phase fraction. During the follow-up period (median, 18.8 months; range, 6-69 months), recurrences were observed in 18 of 48 (37%) cases. The Weibull survival regression model using the enzymatic activity as a continuous covariate showed that levels of enzymatic activity were directly associated with the risk of recurrence (P = 0.02). Assuming the mean value of enzymatic activity as the cutoff value, we found a statistically significant relationship between high MeHPLAase activity and shorter recurrence-free survival. On multivariate analysis, MeHPLAase activity proved to be an independent factor for predicting a short period of recurrence-free survival.


Subject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/pathology , Carboxylic Ester Hydrolases/metabolism , Adult , Aged , Aged, 80 and over , Analysis of Variance , Breast Neoplasms/enzymology , Breast Neoplasms/mortality , Breast Neoplasms/surgery , Carboxylic Ester Hydrolases/analysis , Female , Follow-Up Studies , Humans , Lymph Node Excision , Lymphatic Metastasis , Middle Aged , Mitotic Index , Multivariate Analysis , Neoplasm Metastasis , Neoplasm Recurrence, Local , Postmenopause , Premenopause , Prognosis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Regression Analysis , Survival Rate , Time Factors
15.
J Am Geriatr Soc ; 44(4): 390-3, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8636582

ABSTRACT

OBJECTIVES: To investigate the impact of age as a prognostic factor in older patients with breast cancer and to discuss the role of surgery in this category of patients. DESIGN: A retrospective study. SETTING: A tertiary care university teaching hospital. PARTICIPANTS: One hundred ninety patients aged 70 years or older (mean age: 75 years) were treated for breast cancer from 1967 through 1991. These patients were compared with 190 younger patients (mean age: 52 years) and matched on the basis of T and N categories (TNM staging system) and surgical procedures. MEASUREMENTS: Disease-free survival, breast cancer-specific survival. RESULTS: The 10-year actuarial breast cancer-specific survival was 66% for older patients and 56% for younger patients (P = .224). The 10-year actuarial disease-free survival was 54% for older patients and 45% for younger patients (P = .136). Univariate and multivariate survival analysis revealed that tumor size and nodal stage were significant prognostic factors for both older and younger patients. CONCLUSION: Treatment with curative intent, similar to that adopted in younger patients, is appropriate for women over the age of 70 with breast cancer.


Subject(s)
Breast Neoplasms/mortality , Actuarial Analysis , Adult , Age Distribution , Aged , Aged, 80 and over , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Disease-Free Survival , Female , Humans , Italy/epidemiology , Mastectomy , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Prognosis , Retrospective Studies
16.
Eur J Cardiothorac Surg ; 7(7): 351-5, 1993.
Article in English | MEDLINE | ID: mdl-8396951

ABSTRACT

Fresh surgical specimens of tumors from 60 patients with previously untreated non-small cell lung carcinoma (NSCLC) who underwent radical surgery between January 1991 and October 1992 were investigated by means of flow-cytometry. The nuclear DNA measurement was carried out using a Facscan (Becton, Dickinson, USA). Analysis of the DNA content was performed in all 60 patients whilst cell cycle analysis was possible in 41 cases (68.3%). Forty-two of the 60 cases (70%) were aneuploid and 18 (30%) were diploid. The overall mean value of DNA index was 1.5. Diploid NSCLC were compared with aneuploid tumors: no significant differences in age distribution, sex ratio, histology and staging were found between the two groups (P > 0.05). An S-phase proportion of more than 10% was found in 30 out of 41 patients (73.2%). Early cancer deaths were reported in four patients (6.6%): the aneuploidy rate was very close in these patients (75%) and in the remaining surviving patients (69.6%). An S-phase proportion of more than 10% was found in 100% of early cancer deaths and in 70.2% of the remaining cases; such a difference seems of some importance although it was not statistically significant (P = 0.071). In conclusion, flow-cytometry studies seem to be a useful tool in the understanding of the biological behavior of patients with NSCLC. In the present prospective report there were no significant correlations between DNA measurements and clinical outcome, however, these results suggest that a high S-phase proportion should be seen as a possible prognostic indicator.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Adenocarcinoma/genetics , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Squamous Cell/genetics , DNA, Neoplasm/analysis , Lung Neoplasms/genetics , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adult , Aged , Aneuploidy , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Diploidy , Female , Flow Cytometry , Follow-Up Studies , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasm Staging , Prospective Studies , S Phase
17.
Int Surg ; 69(4): 313-7, 1984.
Article in English | MEDLINE | ID: mdl-6526623

ABSTRACT

From January 1st, 1978 to 31st December, 1981, 28 patients with lung cancer and mediastinal lymph node metastases, underwent surgery. In four patients, only exploration was performed, in five patients, an incomplete resection and in 19 patients, a complete resection (resectability rate 86%). In the first two groups of patients, survival never exceeded two years. In the 'complete resection' group, 78% of the patients survived for one year, 61% for two years and 47% for three years. Patients with adenocarcinoma had a higher three year survival rate than those with squamous cell carcinoma (60% vs. 37%). No 30-day mortality was observed. All patients were treated postoperatively with MACC + BCG. The prognosis of lung cancer classified as N2 is strongly influenced by a series of factors some of which are included in the TNM system. In any case, it would still appear that the best treatment for this kind of tumor is radical surgical resection followed by adjuvant radiotherapy and/or multichemotherapy.


Subject(s)
Adenocarcinoma/surgery , Lung Neoplasms/surgery , Lymph Nodes , Lymphatic Metastasis/surgery , Mediastinum , Adenocarcinoma/mortality , Carcinoma, Squamous Cell/mortality , Humans , Lung Neoplasms/mortality , Prognosis , Retrospective Studies
18.
Ann Ital Chir ; 70(3): 349-53, 1999.
Article in Italian | MEDLINE | ID: mdl-10466237

ABSTRACT

Axillary lymphadenectomy represents one of the historical hallmarks in the surgical strategy for breast cancer treatment. In recent years the role of axillary dissection is becoming matter for a renewed debate: up to date better therapeutic results together with new biologic acquisitions and progresses in early diagnosis have been influencing current indications and extension of axillary lymphadenectomy; also, cosmetic and financial considerations play a relevant role. This is the background of a large number of studies investigating the possibility of a more limited applications of axillary dissection provided that oncologic results remain unchanged. In this context sentinel node biopsy is one of the most promising lines of research. It can be stated that, as far as early stages are concerned, a trend towards more conservative resection techniques that started with the first quadrantectomies two decades ago, is now involving axillary dissection too. Possibly, in the next future, an elective axillary lymphadenectomy will not be performed any more if the presence of positive nodes will not be preliminarily ascertained. Nevertheless such conservative strategy can not be recommended to date, until the technique of sentinel node biopsy will be optimized and its results confirmed by randomized trials.


Subject(s)
Lymph Node Excision , Axilla , Biopsy , Breast/pathology , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Female , Humans , Lymph Nodes/pathology , Lymphatic Metastasis/diagnosis , Lymphatic Metastasis/pathology , Lymphatic Metastasis/prevention & control
19.
Rays ; 22(3): 341-51, 1997.
Article in English, Italian | MEDLINE | ID: mdl-9446938

ABSTRACT

Advances in early diagnosis of breast cancer have allowed most patients to come to treatment at an early stage (in the US in 1993, 75% of cases were stage I-II). In these cases, conservation surgery has played in the last two decades the role of first choice thearpy following randomized studies which definitely showed the same safety and effectiveness as compared to conventional mastectomy. In time, indications for breast conservation therapy underwent modifications as for the size and site of primary tumor, and the presence of concomitant metastases to ipsilateral axillary lymph nodes. Absolute contraindications are still a multicentric diseases, and the presence of diffuse microcalcifications, while tumors over 3 cm in diameter may be amenable to conservation therapy with primary chemotherapy, retroareolar tumors can be resected with central quadrantectomy and clinically evident axillary metastases do not influence local treatment. There are still open problems as for the extent of peritumoral parenchymal excision, indications for complementary radiotherapy and axillary lymphadenectomy.


Subject(s)
Breast Neoplasms/surgery , Mastectomy, Segmental , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Contraindications , Female , Humans , Mastectomy, Segmental/methods , Neoplasm Recurrence, Local , Neoplasm Staging , Radiotherapy, Adjuvant
20.
Rays ; 25(3): 387-91, 2000.
Article in English | MEDLINE | ID: mdl-11367908

ABSTRACT

In breast physiopathology, in spite of the crop of information and clinical studies, a number of questions are still unsolved. The adequacy of research sources and the transmission of information to clinical practice through consistent and validated efficacy evidences are required to ensure the treatment quality. In this article the different specialist approaches and the main themes debated in the interdisciplinary approach to breast cancer are considered: the genetical risk factors, the role of diagnostic imaging, the mapping and assessment of sentinel lymph node, the role of nodal radiation therapy following mastectomy.


Subject(s)
Breast Neoplasms , Female , Humans , Research/trends
SELECTION OF CITATIONS
SEARCH DETAIL